文献速递消化道肿瘤与早癌消化内镜

可替宁验证的吸烟状态变化对息肉切除后异时性结直肠肿瘤风险的影响

Effect of Cotinine-Verified Change in Smoking Status on Risk of Metachronous Colorectal Neoplasia After Polypectomy.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-02-14

该回顾性研究纳入4762例在2010年1月至2014年12月期间结肠镜检出至少1个腺瘤并接受监测结肠镜的患者,依据尿可替宁验证的吸烟状态变化分为4组。持续吸烟者异时性结直肠肿瘤风险显著高于持续不吸烟者(HR 1.54;95%CI 1.36-1.73)和戒烟者(HR 1.63;95%CI 1.39-1.99)。

要点

  • 持续吸烟者异时性结直肠肿瘤风险高于持续不吸烟者(HR 1.54;95%CI 1.36-1.73)。
  • 持续吸烟者异时性进展期结直肠肿瘤风险高于持续不吸烟者(HR 2.84;95%CI 1.79-4.53)。
  • 新吸烟者异时性结直肠肿瘤风险高于持续不吸烟者(HR 1.50;95%CI 1.14-1.97)。

核心结论

  • 在至少1个腺瘤的个体中,可替宁验证的吸烟状态变化与异时性结直肠肿瘤风险相关。
  • 帮助患者戒烟对有效预防结直肠癌很重要。

研究设计与样本

  • 回顾性研究,纳入韩国Kangbuk Samsung健康研究中接受筛查结肠镜并检测尿可替宁的参与者。
  • 分析纳入4762例在2010年1月至2014年12月期间基线结肠镜检出1个或以上腺瘤、并在6个月后至2017年12月期间接受监测结肠镜的患者。

主要发现

  • 按基线至随访结肠镜(平均间隔3.2±1.3年)的可替宁验证吸烟状态变化分为4组:持续不吸烟者(n=2962;第1组)、吸烟转为不吸烟者(n=600;第2组)、不吸烟转为吸烟者(n=138;第3组)、持续吸烟者(n=1062;第4组)。
  • 第4组异时性结直肠肿瘤风险显著高于第1组(HR 1.54;95%CI 1.36-1.73)和第2组(HR 1.63;95%CI 1.39-1.99)。
  • 第4组异时性进展期结直肠肿瘤风险高于第1组(HR 2.84;95%CI 1.79-4.53)和第2组(HR 2.10;95%CI 1.13-3.89)。
  • 第3组异时性结直肠肿瘤风险高于第1组(HR 1.50;95%CI 1.14-1.97)和第2组(HR 1.62;95%CI 1.20-2.20)。

临床怎么用

  • 作者认为,帮助患者戒烟对有效预防结直肠癌很重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Previous assessments of colorectal neoplasia (CRN) recurrence after polypectomy used self-report to determine smoking status. We evaluated the association between change in smoking status and metachronous CRN risk after polypectomy using cotinine level in urine to determine tobacco exposure. METHODS: We performed a retrospective study of participants in the Kangbuk Samsung Health Study in Korea who underwent a screening colonoscopy examination and measurement of cotinine in urine samples. Our analysis included 4762 patients who had 1 or more adenomas detected in an index colonoscopy performed between January 2010 and December 2014, and underwent a surveillance colonoscopy, 6 or more months later, until December 2017. RESULTS: Patients were classified into 4 groups based on the change in cotinine-verified smoking status from index to follow-up colonoscopy (mean interval, 3.2 ± 1.3 y), as follows: remained nonsmokers (n = 2962; group 1), smokers changed to nonsmokers (n = 600; group 2), nonsmokers changed to smokers (n = 138; group 3), and remained smokers (n = 1062; group 4). After adjustment for confounding factors, group 4 had a significantly higher risk of metachronous CRN than group 1 (hazard ratio [HR], 1.54; 95% CI, 1.36-1.73) and group 2 (HR, 1.63; 95% CI, 1.39-1.99). Group 4 also had a higher risk of metachronous advanced CRN than group 1 (HR, 2.84; 95% CI, 1.79-4.53) and group 2 (HR, 2.10; 95% CI, 1.13-3.89). Group 3 had a higher risk of metachronous CRN than group 1 (HR, 1.50; 95% CI, 1.14-1.97) and group 2 (HR, 1.62; 95% CI, 1.20-2.20). CONCLUSIONS: In a retrospective study of individuals with at least 1 adenoma, we found that cotinine-verified changes in smoking status between index and follow-up colonoscopy are associated with a risk of metachronous CRN. Helping patients quit smoking is important for effective prevention of colorectal cancer.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Jung YS, Kim NH, Lee MY, et al. Effect of Cotinine-Verified Change in Smoking Status on Risk of Metachronous Colorectal Neoplasia After Polypectomy. Clin Gastroenterol Hepatol. 2019. PMID: 30772586. doi:10.1016/j.cgh.2019.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。